A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
about
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane ReviewLevetiracetam in the treatment of epilepsyA microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brainProgesterone vs placebo therapy for women with epilepsy: A randomized clinical trial.Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.Data from regulatory studies: What do they tell? What don't they tell?Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?An assessment of levetiracetam as an anti-epileptic drug.Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.Safety profile of levetiracetam.Levetiracetam: a novel antiepileptic drug.Newer therapies in the drug treatment of epilepsy.Levetiracetam: a different approach to the pharmacotherapy of epilepsy.Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trialsUpdate: new uses for lithium and anticonvulsants.Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion.Levetiracetam safety profiles and tolerability in epilepsy patients.Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders.Retrospective study of the use of levetiracetam in childhood seizure disorders.Levetiracetam in pediatrics.Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.The safety of levetiracetam.Rapid dosage titration of levetiracetam in children.The evolution of antiepileptic drugs for mood stabilization and their main mechanisms of action.Levetiracetam: a comprehensive review.Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last.Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis.Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy.Levetiracetam use in the critical care setting.The adverse effects profile of levetiracetam in epilepsy: a more detailed look.The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients.Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature.Levetiracetam for the treatment of status epilepticus.Anticonvulsant drugs for generalized tonic-clonic epilepsy.Levetiracetam Differentially Alters CD95 Expression of Neuronal Cells and the Mitochondrial Membrane Potential of Immune and Neuronal Cells in vitro.A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy
P2860
Q24200332-C90D01E6-3CC4-48BA-A83A-8325F01B3081Q24656333-6396F230-4B47-4CDA-8D30-15BA8BFEF7B1Q28343920-715749F3-8E9A-4037-B118-8B7CBE725BD1Q30418813-BB2436A1-8B7B-4634-B389-B976AAB624FFQ30661918-13ABCF15-53FC-4305-9537-D29B3F4F1439Q30758639-2592A38B-24DE-4FE4-B3DE-76AD384E51BCQ31012430-AE959EED-0540-45F5-918C-FBB4B9EA95BEQ33202111-E0F851E3-2215-4700-B3DD-1B1C148A8D37Q33949491-22086C5F-EFCB-43F4-BD78-EB039ACE3155Q34074969-B5769A5D-F6EF-4525-97B2-EA775DD5E3CEQ34374268-3AA4F622-DBF0-4D3F-99A6-DED3E3C1122AQ34374280-B382442C-08CD-4F38-9E0C-F80B1C0A4F8DQ34443362-8A8BF503-94D1-4DB4-BE46-BE4C793B5484Q34509364-6BD7250A-AB54-4527-BA91-A0E080803F00Q34533863-6BBF0337-50A1-4024-B1F9-A8A15CF7BB7AQ34563933-8D2331CA-D145-4A5E-BEA6-97192AC3531BQ34710521-23152728-A9EB-4A9E-BBEA-1F1A1832ED5EQ35802649-1BCEFA14-E7BD-4CCA-A388-E790C647437BQ35873716-5145B318-F434-402C-A2E5-840F48C7BA43Q35939596-55DB3652-33BB-44E3-8D38-C4619D2E0543Q36037453-AC2FC88F-1660-4603-A013-B49D27CFAFDEQ36081844-23D1071A-4F05-41C2-96A2-E446FC89476AQ36284727-596408CD-5E7C-4E8C-8D03-9D63FA3C32C4Q36789988-D607B574-45FA-4600-85E6-74C437064AE6Q36802676-FF7E171B-D35C-4A8B-A781-E880F4ED7C66Q36811528-D9E70FC5-FB20-4E42-868E-0E080EB17061Q37092273-0D94EA16-42AD-4F94-927C-3E75B7C74E59Q37610170-DC5253B8-9F6B-4BEC-B319-E1C695774BEBQ37688063-FD5F6537-7B8D-4972-B476-CE380FFB1BD8Q37733552-48FB431E-F069-43D0-91A4-FF97CC99EE6EQ37975526-4A73BE6B-9A6C-44EC-AF05-CEB4B46E7028Q38064486-CF0FCD36-6B62-4363-8A08-318D335961D2Q38132386-3CE24733-A5E9-4024-90FB-CBCECB1C7B35Q38164431-D6785D52-0389-4E0D-86E0-2D1E65B1469AQ38172904-51F24220-811A-451A-958A-59FD9A6194D3Q38395668-4B668528-763D-43BA-BF5A-A18F8CB992F0Q38594849-65CE63E8-E36F-44E5-A17F-61584FF9DBACQ38798288-A1413DB0-D656-4E53-B0A8-E062830D3619Q39237618-9DF2033C-F04A-42D5-AEC6-F46F0BFF4206Q41834749-AD26EA63-62FD-4C9A-979C-7CF723A3CFC1
P2860
A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@en
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@nl
type
label
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@en
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@nl
prefLabel
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@en
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@nl
P2093
P356
P1476
A multicentre, double-blind, r ...... ents with refractory epilepsy.
@en
P2093
P356
10.1053/SEIZ.2000.0380
P577
2000-03-01T00:00:00Z